1、Q1 2025 EARNINGS CALLELI LILLY AND COMPANY2025 Q1 EARNINGSIntroduction and Key EventsDave Ricks,Chair and Chief Executive OfficerQ1 2025 Financial ResultsLucas Montarce,Chief Financial OfficerR&D UpdateDan Skovronsky,M.D.,Ph.D.,Chief Scientific OfficerClosing RemarksDave Ricks,Chair and Chief Execut

2、ive OfficerQuestion&Answer SessionAgenda32025 Q1 EARNINGSNot for promotional use4Safe Harbor Provision and Other InformationThis presentation contains forward-looking statements that are based on managements current expectations,but actual results may differ materially due to various factors.The com

3、panys results may be affected by factors including,but not limited to,the risks and uncertainties in pharmaceutical research and development;competitive developments;regulatory actions;litigation and investigations;business development transactions;economic conditions;and changes in laws and regulat

4、ions,including healthcare reform.For additional information about the factors that affect the companys business,please see the companys latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission.Certain financial information in this presentation is presented

5、 on a non-GAAP basis.Investors should refer to the reconciliations included in this presentation and should consider the companys non-GAAP measures in addition to,not as a substitute for or superior to,measures prepared in accordance with GAAP.These materials are not intended to promote the products

6、 referenced herein or otherwise influence healthcare prescribing decisions.The safety and efficacy of the agents under investigation have not been established.There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated.The c